WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Scottie Scheffler's Louisville court date postponed after arrest during PGA Championship
Glimpses of Beijing through windows and doorways
Takeaways from AP report on how the search for the coronavirus origins turned toxic
Shooting injures 2 at Missouri high school graduation ceremony
Sir Keir's patriotism problem: One
Olivia Dunne shares selfie in all
China's top political advisory body starts annual session
IF starring Ryan Reynolds lands at the top of a lackluster box office with less
PNG leader takes offense after Biden implies an uncle was eaten by cannibals
Harris accepts debate invite to face off with Trump's VP pick, which may come at convention
Yankees pitcher Luis Gil gets 2nd big league win, 993 days after beating Orioles in debut